Background: The phosphotidylinositol-3 kinase (PI3K)/serine-threonine kinase/mammalian target of rapamycin signaling pathway is frequently altered in head and neck squamous cell cancer (HNSCC). PX-866 is an oral, irreversible, pan-isoform inhibitor of PI3K. A phase I trial demonstrated tolerability of this combination. This randomized phase II study evaluated PX-866 combined with cetuximab in patients with advanced, refractory HNSCC.
introduction
The phosphotidylinositol-3 kinase (PI3K)/serine-threonine kinase (AKT)/mammalian target of rapamycin (mTOR) signaling pathway is frequently altered in human cancers, leading to cellular proliferation, increased expression of survival genes, and decreased expression of proapoptotic signals [1] . PI3K is an intracellular kinase comprised of the p110α, p110β, or p110δ catalytic subunits, and a p85 regulatory subunit; mutations of p110α and p85 can be oncogenic [2, 3] . Activating genetic events in PIK3CA, be it mutations [2, [4] [5] [6] [7] [8] [9] , or increased PIK3CA copy number [10] [11] [12] are common. Lastly, upstream growth factor receptors that activate PI3K signaling, such as epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor, are often overexpressed [13, 14] .
PX-866 is a novel oral, pan-isoform inhibitor of PI3K [15] . PX-866 had substantial antitumor efficacy in preclinical studies using head and neck squamous cell cancer (HNSCC) patient-derived xenograft (PDX) models with and without a PIK3CA-activating genetic event [16] .
The EGFR is a receptor tyrosine kinase integral to the development and proliferation of HNSCC [17] , and therapies targeting EGFR are in common use in relapsed/metastatic (R/M) HNSCC [18] . One mechanism of resistance to EGFR inhibition is enhanced signaling through the PI3K/AKT/mTOR pathway [19] [20] [21] [22] . PX-866 reversed gefitinib resistance in lung cancer xenografts, and PX-866 combined with cetuximab was more effective than cetuximab alone in patient-derived HNSCC xenografts [23, 24] .
Given this rationale and the fact that cetuximab and PX-866 have nonoverlapping toxicity profiles (with the exception of diarrhea), a dose escalation study of cetuximab and PX-866 was conducted in patients showing good tolerability and a promising 44% response rate [25] . Thus, we conducted an open-label, randomized, phase II trial comparing cetuximab plus PX-866 versus cetuximab alone in second-or third-line R/M HNSCC. methods eligibility Subjects had R/M HNSCC for which they had received one to two prior systemic therapies, including up to one platinum-based chemotherapy regimen. Inclusion criteria were signed informed consent, age ≥18 years, measurable disease by RECIST 1.1 [26] , ECOG 0-1, life expectancy ≥3 months, and adequate hematologic, hepatic, and renal function. Exclusion criteria included systemic anticancer or radiation within 4 weeks, HIV infection; any factor affecting safety or compliance; grade ≥2 neuropathy; hypersensitivity to cetuximab; pregnant/breastfeeding; prior cetuximab for R/M HNSCC or within 6 months of enrollment with radiation; or prior PI3K inhibitor. Each center's institutional review board granted approval. Baseline characteristics were similar between the two arms, with the exception of an unexplained imbalance in gender that was statistically significant (33% versus 7% females in arms A and B, respectively; P < 0.05). Figure 1A , available at Annals of Oncology online). Median overall survival (OS) was 211 days in arm A (95% CI 149-279) and 256 days in arm B (95% CI 148-NR; P = 0.62, supplementary Figure 1B , available at Annals of Oncology online).
treatment and efficacy

crossover
Seventeen patients crossed over to combination therapy upon progression and no CR or PR occurred. Best response was SD in seven subjects, with a disease control rate of 41% at week 12 after crossover. The median number of cetuximab doses after crossover was 6.0 (range, 1-36). Median time to progression was 78 days (95% CI 41-86 days) precrossover for those 17 patients, and 41 days (95% CI 38-87 days) after crossover.
human papillomavirus
Human papillomavirus (HPV) was conducted centrally by assessing p16 by immunohistochemistry (IHC). Of the 46 patients with available tissue, 26 patients (57%) were HPV+ and 20 (43%) were HPV− (supplementary Table S1 , available at Annals of Oncology online). There were 13 HPV+ patients randomized to each of the arms. Of the 13 patients that received therapy for seven or more cycles (not counting crossover subjects), none were HPV+, 4 (31%) were HPV−, and 9 (69%) had an unknown status. Of the seven patients who had a confirmed PR, none were HPV+, two (29%) were HPV−, and five (71%) had an unknown status.
genomics
Of the 46 patients whose archival tumors were analyzed, 8 (17%) had PIK3CA exon 9 mutations: 7 G1633A and 1 G1624A, 4 in each arm. Of these patients, six were HPV+ and two were HPV− while one had a co-existing KRAS mutation in exon 12. PTEN expression was reduced or absent in four patients (two in arm A, two in arm B; two HPV+, two HPV−). There were no responses in any of the eight patients whose tumors harbored a PIK3CA mutation, and neither of these patients remained on treatment of longer than six cycles. KRAS mutations and PTEN IHC could not be correlated with objective response rate (ORR) due to their low frequency.
safety and tolerability
Seventy-nine enrolled patients received at least one treatment on protocol and were considered assessable for safety (40 in arm A 3%) . Rash occurred in 45% of patients in arm A and 31% of subjects in arm B, but dry skin and dermatitis were similar between groups. Deaths during the study, three in arm A and four in arm B, were due to disease progression. Three patients in each arm were taken off study due to toxicity. Patients in the crossover cohort experienced 94 AEs, of which 13 were grade 3 and 1 was grade 4.
discussion
We report the results of a prospective, randomized study of cetuximab plus/minus a small molecule inhibitor PX-866 targeting PI3K in R/M HNSCC patients. The primary question of this trial was answered unequivocally; the addition of PX-866 to cetuximab failed to improve PFS, ORR, or OS in patients with R/M HNSCC. It is possible that the lack of clinical benefit resulted from lack of molecular preselection in this study, as very few tumors harbored the genetic alterations (PIK3CA mutations, PTEN loss) thought to predict sensitivity to PI3K inhibitors. The observed response rate to cetuximab was in line with recently reported randomized studies in this patient population [27] .
It has been difficult to identify predictive biomarkers for any tumor type for PI3K inhibitors. Preclinical and clinical data suggest that PI3K pathway activation may correlate with sensitivity to PI3K inhibitors [16, 19, [28] [29] [30] [31] . In our laboratory experience, PX-866 had antitumor activity in a HNSCC PDX in cases with PIK3CA-activating mutations or gene amplification, although activity was also seen in cases without any such genetic events [16] . PIK3CA mutations appeared to be nonstatistically significantly associated with longer duration of stable disease in the phase I studies of PX-866 and BKM-120 [29, 31] . On the other hand, the PI3K inhibitor XL187 inhibited the PI3K pathway but both pharmacodynamic and clinical activity occurred irrespective of tumor PI3K pathway molecular alterations [32] .
Classification of HNSCC patients according to HPV, retrospectively at the very least and ideally prospectively, is an essential component of contemporary clinical trial design. Fifty-seven percent of patients tested were HPV+. We did not identify Although the addition of PX-866 to cetuximab was reasonably well tolerated, toxicity was more pronounced in the combination arm, though patients come off-study due to toxicity similarly between arms, and the cetuximab dose intensity was equivalent. This was particularly evident in the incidence of gastrointestinal toxicities (nausea, vomiting, and diarrhea), leading to electrolyte imbalances. However, the number of severe AEs was similar between arms. Many of observed AEs are consistent with other phase I/II studies evaluating PI3K inhibitors including our own prior phase I study [25] . Combinations of EGFR inhibitors and targeted agents has been challenging in HNSCC and sometimes not achievable [33] ; this combination was feasible, and is one of the largest trials in HNSCC exploring a targeted agent aimed at a pathway other than EGFR [34] .
We can speculate about potential reasons why this trial was not successful. We did not see glycemic toxicity, and some have argued that this suggests poor target inhibition; PX-866 is not the sole PI3K inhibitor (e.g. XL147) lacking glycemic toxicity [32] . Because we did not have tumor biopsies (or the trials with PX-866 that preceded it) we cannot ascertain this question. Although 7 of 17 patients achieved stability for 12 weeks in the crossover cohort, no responses were seen.
In summary, the addition of PX-866 to cetuximab did not improve clinical outcomes compared with cetuximab alone in a molecularly unselected population of R/M HNSCC patients. Although it can be argued that future investigations with PI3K inhibitors in HNSCC should focus on appropriate biomarker selection to maximize the chances of clinical benefit, a strong link between PI3K inhibitor activity and PIK3CA-activating genetic events has been elusive. 
